Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Richard Harrop

Oxford BioMedica (UK) Ltd

The Medawar Centre

Oxford Science Park

Oxford

[email]@oxfordbiomedica.co.uk

Name/email consistency: high

[Claim this account]

Affiliations

Oxford BioMedica (UK) Ltd, The Medawar Centre, Oxford Science Park, Oxford, UK. 2006 - 2012
Department of Biology, University of York. 2000

References

Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax). Harrop, R., Treasure, P., de Belin, J., Kelleher, M., Bolton, G., Naylor, S., Shingler, W.H. Cancer Immunol. Immunother. (2012) [Pubmed]
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Harrop, R., Shingler, W.H., McDonald, M., Treasure, P., Amato, R.J., Hawkins, R.E., Kaufman, H.L., de Belin, J., Kelleher, M., Goonewardena, M., Naylor, S. Cancer Immunol. Immunother. (2011) [Pubmed]
Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. Harrop, R., Shingler, W., Kelleher, M., de Belin, J., Treasure, P. J. Immunother. (2010) [Pubmed]
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Harrop, R., Drury, N., Shingler, W., Chikoti, P., Redchenko, I., Carroll, M.W., Kingsman, S.M., Naylor, S., Griffiths, R., Steven, N., Hawkins, R.E. Cancer Immunol. Immunother. (2008) [Pubmed]
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Harrop, R., Drury, N., Shingler, W., Chikoti, P., Redchenko, I., Carroll, M.W., Kingsman, S.M., Naylor, S., Melcher, A., Nicholls, J., Wassan, H., Habib, N., Anthoney, A. Clin. Cancer Res. (2007) [Pubmed]
Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Harrop, R., Ryan, M.G., Myers, K.A., Redchenko, I., Kingsman, S.M., Carroll, M.W. Cancer Immunol. Immunother. (2006) [Pubmed]
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Harrop, R., Connolly, N., Redchenko, I., Valle, J., Saunders, M., Ryan, M.G., Myers, K.A., Drury, N., Kingsman, S.M., Hawkins, R.E., Carroll, M.W. Clin. Cancer Res. (2006) [Pubmed]
Characterization, cloning and immunogenicity of antigens released by transforming cercariae of Schistosoma mansoni. Harrop, R., Jennings, N., Mountford, A.P., Coulson, P.S., Wilson, R.A. Parasitology (2000) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.